Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Green Cross Corp
Green Cross Corp
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
You need to be a subscriber to read this article.
Click here
to find out more.
Pharmaceutical
A bullish time for biotech
Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Design & Build
Green Cross Biotherapeutics begins construction in Montreal
The CA$315m biopharmaceutical facility will employ 200 professionals
Pharmaceutical
Green Cross and Nanolek agree partnership for biologics commercialisation in Russia
Nanolek will license the technology and manufacture a number of biologics for Green Cross
Finance
Green Cross expands cell therapy business in China
Company to build a cell therapy facility in the southwestern Chinese province to produce and distribute cell therapy products in China
Manufacturing
PBS Biotech signs up GCMS as bioreactor distributor in Korea
Offers Korean biopharmas technology to produce drugs, vaccines and biosimilars for global market
Subscribe now